ArticleJournal of artificial organs : the official journal of the Japanese Society for Artificial Organs2018
Diagnosis, medical treatment, and stepwise mechanical circulatory support for fulminat myocarditis.
Article in Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Early temporary ventricular assist device intervention improves survival in fulminant myocarditis with cardiogenic shock: experience from a single centre and national cohort.Frontiers in cardiovascular medicine · 2026Article
- Venoarterial extracorporeal membrane oxygenation using magnetic levitation centrifugal pumps for fulminant myocarditis in infants, children and young adults.Translational pediatrics · 2024Article
- Comparison of predictors of survival among fulminant myocarditis patients undergoing veno-arterial extracorporeal membrane oxygenation in the adult and pediatric populations.Annals of medicine and surgery (2012) · 2024Article
- Clinical Application of Extracorporeal Membrane Oxygenation in the Treatment of Fulminant Myocarditis.Reviews in cardiovascular medicine · 2024Review
- Mechanical Circulatory Support Systems in Fulminant Myocarditis: Recent Advances and Outlook.Journal of clinical medicine · 2024Review
- Left ventricular function changes and echocardiographic predictors in adult survivors of fulminant myocarditis treated with the Chinese protocol.Scientific reports · 2023Article
- Differences in Prognosis and Cardiac Function According to Required Percutaneous Mechanical Circulatory Support and Histological Findings in Patients With Fulminant Myocarditis: Insights From the CHANGE PUMP 2 Study.Journal of the American Heart Association · 2022Article
- Veno-Arterial Extracorporeal Membrane Oxygenation in Patients with Fulminant Myocarditis: A Review of Contemporary Literature.Medicina (Kaunas, Lithuania) · 2022Review
- Cardiogenic shock with highly complicated course after influenza A virus infection treated with vva-ECMO and Impella CP (ECMELLA): a case report.BMC cardiovascular disorders · 2021Article
- Total percutaneous biventricular assist device implantation for fulminant myocarditis.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2021Article
- Extracorporeal Membrane Oxygenation for Fulminant Myocarditis: Increase of Cardiac Enzyme and SOFA Score Is Associated with High Mortality.Journal of clinical medicine · 2021Article
- Overview of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiogenic Shock.Frontiers in cardiovascular medicine · 2021Review
- Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes.Signal transduction and targeted therapy · 2020Review
- Experience with Temporary Centrifugal Pump Bi-ventricular Assist Device for Pediatric Acute Heart Failure: Comparison with ECMO.Pediatric cardiology · 2020Article
- Clinical characteristics and treatment effects of astragalus injection in non-pediatric patients with acute fulminant myocarditis.Medicine · 2020Article
- Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.Circulation. Heart failure · 2020Review
- Central conversion from peripheral extracorporeal life support for patients with refractory congestive heart failure.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2020Article
- Temporal echocardiography findings in patients with fulminant myocarditis: beyond ejection fraction decline.Frontiers of medicine · 2020Article
- Successful treatment of fulminant myocarditis in an adult in emergency department: A case report.Medicine · 2019Article
- Successful Treatment of Acute Fulminant Eosinophilic Myocarditis in a Patient with Ulcerative Colitis Using Steroid Therapy and Percutaneous Cardiopulmonary Support.Internal medicine (Tokyo, Japan) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fulminant myocarditis is one of the most challenging diseases. We sought to examine the outcomes of our multidisciplinary treatment strategy for fulminant myocarditis. A retrospective review of consecutive 30 patients with fulminant myocarditis was conducted. Of the 30 patients, 25 required mechanical circulatory support (MCS). Percutaneous extracorporeal membrane oxygenation (ECMO) was the first-line therapy to rescue the patients and inserted in 23 of them. The other 2 were implanted with temporary ventricular assist device (t-VAD) with extracorporeal centrifugal pump(s). Sixteen of the ECMO-supported patients were later transitioned to t-VAD. Of the 18 patients who underwent t-VAD support, heart function recovered and the VAD was explanted in 10. Four patients were bridged to long-term VAD and the other 4 died on t-VAD. Two patients were directly bridged to long-term VAD by ECMO. Heart function recovered only with ECMO in 4 patients and 1 died on ECMO. Overall survival rate was 83.3%. The duration of ECMO support significantly correlated with total bilirubin level, which was a significant risk factor for mortality. Pathologically, 7 patients (23.3%) had eosinophilic myocarditis and 1 (3.3%) had giant-cell myocarditis, and all the 8 patients underwent immunosuppressive therapy including steroids. Heart function recovered to normal level in 7 of them (87.5%). Timely conversion from the percutaneous ECMO to the temporary VAD before elevation of total bilirubin level is crucial for improving the clinical outcomes. Endomyocardial biopsy is needed to be done as soon as possible, because immunosuppressive therapy carries promising outcomes in certain etiologies.
Indexed as
Identifiers
29236180What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.